GlassScriptPhysician profile
Tamara L Simpson
NPI 1881128643
$18,326.71
in general payments reported to CMS, 2019-2025
52 companies · $3,601 in 2025
The $3,601 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,250 · 2022: $3,633 · 2023: $4,003 · 2024: $3,840 · 2025: $3,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,375.92 |
| Education | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,492.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,656.10 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,782.52 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,687.72 | 2021-2025 | Nucala, Arexvy, Shingrix |
| Amgen INC. | $1,119.59 | 2021-2025 | Evenity, Prolia, Krystexxa |
| Astellas Pharma US INC | $931.69 | 2021-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $910.56 | 2021-2025 | Zepbound, Mounjaro, Taltz |
| Novartis Pharmaceuticals Corporation | $739.51 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $530.74 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $517.96 | 2021-2025 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $415.37 | 2021-2024 | Verquvo, Belsomra, Januvia |
| Pfizer INC. | $373.94 | 2021-2025 | |
| Axsome Therapeutics, INC. | $269.09 | 2023-2025 | Auvelity |
| Nestle Healthcare Nutrition INC. | $235.65 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $227.94 | 2023-2025 | Gemtesa |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.